EUCTR2006-004407-19-DE进行中（未招募）不适用
A multi-center, double-blind, randomized, placebo-controlled, dose-ranging phase 2 study to investigate pharmacodynamics, safety, tolerability and pharmacokinetics of RO5073031 in patients with type 2 diabetes mellitus treated with a stable dose of metformin (BC20688)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Type 2 diabetes mellitus patients treated with individual maximum tolerated daily dose of metformin monotherapy (metformin daily dose = 1.5 g, maximum not higher than recommended in the label) for at least 3 months prior to screening.
- •-Males, postmenopausal women (defined as more than two years after the cessation of menses) or surgically sterilized women.
- •-Age 18 to 75 years at the time of the screening examination.
- •-HbA1c = 7.0 % and = 9.5 % at screening.
- •-Fasting plasma glucose (FPG) > 126 mg/dL (7.0 mmol/L) and = 240 mg/dL (13.3 mmol/L) at screening.
- •-BMI > 25 kg/m2 and = 45 kg/m2 at screening
- •-Stable weight ± 10% for at least 3 months before screening.
- •-Patients able and willing to give written informed consent and to comply with the requirements of the study (patients that cannot follow blood glucose selfmonitoring and study requirements independently from another person cannot be included).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Type 1 diabetes mellitus patients
- •-Known hypersensitivity to RO5073031 or any of its components.
- •-Known contraindications to metformin, i.e.
- •-Congestive heart failure requiring pharmacologic treatment;
- •-Clinically significant respiratory insufficiency.
- •-History of ketoacidosis or lactic acidosis.
- •-Treatment with any anti-hyperglycemic medication other than metformin monotherapy during the last 3 months (except insulin use in acute situations or
- •during surgery for up to 7 days).
- •-Any previous exposure to GLP-1, GLP-1 analogues or exenatide before the study.
- •-Systemic use of corticosteroids in the last 3 months.
- •-Use of weight lowering medications (orlistat, sibutramine, rimonabant, phentermine) in the last 3 months.
- •-Patients receiving ACE inhibitors, beta-blockers, thiazide diuretics, thyroid hormones, and/or lipid lowering medications who are not on a stable dose for
- •more than 6 weeks prior to the start of the study.
- •-Impaired liver function (ALAT or ASAT or total bilirubin or alkaline phosphatase > 2.5x ULN) at screening.
- •-Renal disease or renal dysfunction (as suggested by serum creatinine levels = 1.5 mg/dL [males], = 1.4 mg/dl [females]) at screening.
- •-Uncontrolled hypertension (SBP > 160 mmHg and/or DBP > 100 mmHg, despite treatment) at the time of the screening examination.
- •-Myocardial infarction or stroke within 6 months prior to the screening examination.
- •-Known hemoglobinopathy.
- •-Known proliferative diabetic retinopathy.
- •-Clinically significant GI disease including inflammatory bowel disease, irritable bowel
- •syndrome, celiac disease, dyspepsia, apparent diabetic gastroparesis, diabetic diarrhoea, or surgery of the gastro-intestinal tract (except appendectomy / cholecystectomy).
- •-Any abnormality in clinical laboratory tests or ECG, which precludes safe involvement in the study as judged by the investigator.
- •-Pregnant or lactating women or women of childbearing potential.
- •-Participation in an investigational drug study within 90 days [3 months] (or treatment with any investigational agent within five half-lives of that investigational drug, whichever is longer) prior to screening.
- •-Serious illness, such as active cancer, major active infection, severe psychiatric disorders at the time of the screening examination.
- •-Alcohol or drug abuse.
研究者
相似试验
进行中（未招募）
1 期
A medical research study to evaluate the effects of ACT-246475 in adults with coronary artery disease.stable coronary artery diseaseMedDRA version: 20.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2017-003332-36-DKIdorsia Pharmaceuticals Ltd.324
进行中（未招募）
不适用
A study to assess efficacy and safety of selexipag in subjects with Raynaud's Phenomenon secondary to Systemic SclerosisEUCTR2014-000865-34-GBActelion Pharmaceuticals Ltd70
进行中（未招募）
1 期
A multi-center, double-blind, randomized, placebo-controlled, titration study to investigate the safety, the tolerability and the pharmacodynamic profiles of different doses of RO5073031 in patients with type 2 diabetes mellitus treated with a stable dose of metformin.Type 2 diabetes mellitusMedDRA version: 8.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2006-006273-25-FRF. Hoffmann-La Roche Ltd120
进行中（未招募）
1 期
A medical research study to evaluate the effects of ACT-246475 in adults with coronary artery disease.stable coronary artery diseaseMedDRA version: 20.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2017-003332-36-NLIdorsia Pharmaceuticals Ltd.324
进行中（未招募）
1 期
Study to evaluate if macitentan is efficient, safe and tolerable enough to be used for treatment of Eisenmenger syndrome.MedDRA version: 18.0Level: PTClassification code 10058554Term: Eisenmenger's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEisenmenger SyndromeEUCTR2012-003335-33-CZActelion Pharmaceuticals Ltd.220